Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04549038
Other study ID # 2019-1180
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 19, 2020
Est. completion date November 18, 2022

Study information

Verified date February 2023
Source Children's Hospital Medical Center, Cincinnati
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Circadian cycles, metabolism, and nutrition are intimately linked, and the timing of meals play an important role in synchronizing peripheral circadian rhythms. There are little data describing the influence of nocturnal feeds on sleep, metabolism, and overall health in hospitalized children. To evaluate this association, the investigators will conduct a single-center, randomized, non-blinded controlled trial that will test the impact of nocturnal enteral/parenteral nutrition on patient outcomes.


Description:

HSCT provides a potential cure for children and adults with high risk and relapsed malignancy, immune deficiency, and other fatal illnesses. Circadian cycles, metabolism, and nutrition are intimately linked, and the timing of meals play an important role in synchronizing peripheral circadian rhythms; however, the standard of care for HSCT recipients is to deliver continuous feeds (either enterally or parenterally). The objective of this study is to evaluate the influence of the timing of feeding on sleep and metabolism in HSCT subjects. The investigators hypothesize patients receiving feeds during daytime hours (0800-2000) in comparison to continuous (24 hours), will have improved sleep efficiency, decreased blood glucose, insulin, and triglycerides over patients who receive feeding overnight. The aim of this study is to evaluate the influence of the timing of feeds on sleep, metabolism, and outcomes in HSCT subjects.


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date November 18, 2022
Est. primary completion date August 25, 2022
Accepts healthy volunteers No
Gender All
Age group 12 Months and older
Eligibility Inclusion Criteria: - Patients >/= 12 months of age undergoing HSCT and receiving a myeloablative preparative regimen Exclusion Criteria: - Prior history of hypoglycemia, diabetes mellitus, metabolic disease, or other requirement for continuous nutrition

Study Design


Related Conditions & MeSH terms

  • Hematopoietic Stem Cell Transplant

Intervention

Other:
12-16 hour nutrition
Cases will receive their nutrition over a period of 12-16 hours, with minimum 8 hours of fasting and maximum 12 hours of fasting. Feeding will begin in morning hours unless otherwise directed by an investigator or registered dietician.

Locations

Country Name City State
United States Cincinnati Children's Hospital Cincinnati Ohio

Sponsors (1)

Lead Sponsor Collaborator
Children's Hospital Medical Center, Cincinnati

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of wake episodes Number of wake episodes 21 days
Primary Duration of wake episodes Duration of wake episodes 21 days
Secondary Hypertension Incidence of hypertension 21 days
Secondary Weight change Change in weight at day +7, +14, and +21 from day 0 21 days
Secondary Time to tolerating oral feeds Number of days post-transplant until the patient tolerates feeds/nutrition 21 days
Secondary Neutrophil engraftment Time to absolute neutrophil count >500 21 days
Secondary Cortisol levels 3 times weekly morning cortisol levels 21 days
Secondary Triglyceride levels Weekly triglyceride levels 21 days
Secondary Glucose levels Daily glucose levels 21 days
See also
  Status Clinical Trial Phase
Withdrawn NCT02451462 - Pilot Trial of Zoledronic Acid to Prevent Bone Loss in Hematopoietic Cell Transplant Recipients N/A
Terminated NCT01215981 - Influenza Vaccine Post Allogeneic Transplant N/A
Recruiting NCT03613532 - Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN Phase 1
Completed NCT01337648 - Radiation Biodosimetry in Children Undergoing Total Body Irradiation N/A
Recruiting NCT03250546 - Haploidentical and Mismatched Unrelated Donors Hematopoietic Stem Cell Transplant Phase 2
Recruiting NCT02982902 - T Cell Therapy of Opportunistic Cytomegalovirus Infection Early Phase 1
Completed NCT02441075 - 70% Ethanol for Decontamination of CVL Exposed to Calcineurine Inhibitors Version 1.0, 1/9/2014 N/A
Not yet recruiting NCT05722210 - Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant
Completed NCT03886909 - Impact of Prehabilitation in Oncology Via Exercise- Bone Marrow Transplant N/A
Not yet recruiting NCT06328127 - Positive Psychology Intervention for Hematopoietic Stem Cell Transplantation Survivors N/A
Completed NCT03509051 - Prospective Study on the Vaccine Response to Meningococcal B Vaccine After Allogeneic Stem Cell Transplantation N/A
Terminated NCT02350777 - T-cell Depleted Hematopoietic Stem Cell Boosts Without Conditioning for Poor Marrow Graft Function Following Allogeneic Hematopoietic Stem Cell Transplantation Phase 2
Completed NCT04853277 - Patient Reported Outcomes and Patient Education in Cellular Therapy Patients N/A
Completed NCT03378089 - Music Therapy and Hematopoietic Stem Cell Transplant N/A
Completed NCT03039257 - Vitamin A Replacement in Patients Undergoing HSCT and Its Role on MBI-LCBI Rates N/A
Completed NCT03202849 - A Randomized Trial of Vitamin D Supplementation With or Without Vitamin A in Stem Cell Transplantation N/A
Completed NCT01504152 - International Travel Patterns and Health Preparations of Hematopoietic Stem Cell Transplant Recipients at Memorial Sloan-Kettering Cancer Center N/A
Completed NCT01581164 - Studies of the Immune Response to Vaccination After Hematopoietic Stem Cell Transplantation N/A
Completed NCT03759262 - Ultra-high Dose Vitamin D for HSCT N/A
Recruiting NCT04263597 - Oral Supplementation of 2'-Fucosyllactose in Allogeneic Bone Marrow Transplant Recipients Phase 1/Phase 2